Qiagen extends its recent high, shares near 52-week peak on NYSE and Xetra

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 11:56.

Qiagen N.V. (NL0012169213) continues to trade close to its recent 52-week high, with the primary listing on the NYSE under ticker QGEN and a secondary line in Frankfurt and on Xetra providing additional liquidity for European investors.MarketBeat price data on Qiagen The stock closed at 38.95 US dollars on the NYSE on June 25, 2026, while the German line recently printed around 34.52 euros on Xetra, illustrating a robust cross-market presence.Finanzen100 Xetra quote for Qiagen

What recent trading shows

On the NYSE, Qiagen shares ended the June 25, 2026 session at 38.95 US dollars, up 0.22 dollars or 0.56 percent, with extended trading indicating a marginal 0.02 dollar tick down to 38.93 dollars shortly after the close.MarketBeat closing data for QGEN The 52-week range on this line currently stretches from roughly 30 US dollars on the downside to just above 40 US dollars, marking the recent level as close to the upper end of the band.TradingKey sentiment on Qiagen NV

In Germany, the Qiagen shares with WKN A41HBE and ISIN NL0015002SN0 most recently traded around 34.52 euros on Xetra, a level that represents a gain of roughly 1.5 percent on the day of the last quote and provides a useful cross-check on valuation in euro terms.Finanzen100 quote and performance data The co-existence of NYSE and Xetra listings, alongside Frankfurt and Tradegate activity, underlines the stock’s visibility in both the S&P 500-linked US healthcare universe and the European mid-cap biotech and diagnostics peer group.

Analyst stance and sector peers

Analyst coverage on Qiagen remains active, with Morgan Stanley upgrading the stock to Overweight from Equal Weight earlier this year and lifting its price target to 42 US dollars from 40 US dollars, signaling increased confidence in earnings and cash flow resilience in molecular diagnostics.Intellectia summary of recent Qiagen analyst moves Kepler Cheuvreux initiated coverage with a Hold rating and a 38.60 US dollar target, framing the valuation as fair relative to the growth profile but less compelling than some faster-growing peers in sequencing and genomic testing.Kepler Cheuvreux stance via Intellectia

In the broader sector, Qiagen competes with diagnostics and life-science tools names such as Thermo Fisher Scientific, Roche Diagnostics and Abbott Laboratories, which together define the competitive landscape in sample preparation, PCR and sequencing workflows. The mixed rating profile, with at least one Overweight recommendation and a Hold stance, places Qiagen between more aggressively rated growth stories and more mature, dividend-oriented healthcare groups, while the proximity to a 52-week high suggests investors have rewarded consistent earnings delivery and product uptake in clinical and research laboratories.

The product behind the stock

Qiagen generates revenue primarily from sample-to-insight solutions that span nucleic acid extraction, PCR and next-generation sequencing, anchored by platforms such as the QIAstat-Dx syndromic testing system and the QIAcube sample processing instruments. These products are used in clinical diagnostics, academic research and pharmaceutical development, supporting workflows from pathogen detection to oncology biomarker analysis and helping laboratories standardize and automate complex molecular procedures.

Where the stock trades today

Qiagen N.V. shares (NL0012169213) most recently traded at 38.95 US dollars on the NYSE at the close on 2026-06-25, with the parallel Xetra listing last quoted at approximately 34.52 euros on 2026-06-25, illustrating the current valuation range across the US and German venues.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any transaction. All data and assessments are based on sources believed to be reliable as of the stated dates but may change without notice.